Regarding ESA, the Red-HF study demonstrated an improvement in Hb in the ESA group, but the primary endpoint (all-cause death and re-admission because of worsening of heart failure) was not significantly different from the placebo group [5]. This evidence concerns the gene GSTM1 and hydrops fetalis.